NDA for the treatment of endometriosis is expected to be filed by the end of the company's current fiscal year (July 31), Syntex Chairman Albert Bowers told analysts in New York Jan. 18. Bowers also noted that the company has four NDAs pending at the agency, including Cardene, Ticlid, Gardrin and Toradol. The injectable pain killer Toradol (ketorolac) has been given a 1-B rating by the agency, Bowers said.
You may also be interested in...
Seattle Genetics holds the award for fastest supplemental approval (11 days) and fastest new molecular entity approval (119 days) under the US FDA's RTOR program, according to the Pink Sheet's Performance Tracker.
Technology modernization efforts, the expansion of cloud-based submission capabilities, and the ongoing COVID-19 pandemic could serve as catalysts to broaden FDA’s Real-Time Oncology Review program beyond cancer therapeutics, Pfizer exec Richard Jahn says.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.